Existing fixed-duration regimens using first-generation Bruton tyrosine kinase inhibitor (BTKi) monotherapy have important efficacy and/or safety limitations. AMPLIFY is the first randomized study to evaluate a fixed-duration regimen of venetoclax with a second-generation BTKi in patients with chronic lymphocytic leukemia (CLL). Results were presented at the 2024 ASH Annual Meeting & Exposition.
